# Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

> **NCT05335447** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 5 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG3667 capsule
- **DRUG:** [14C]-GLPG3667 solution for infusion
- **DRUG:** [14C]-GLPG3667 capsule

## Key facts

- **NCT ID:** NCT05335447
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-19
- **Primary completion:** 2022-06-03
- **Final completion:** 2022-06-03
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335447, "Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05335447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*